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Abstract
Objective: The purpose of this study was to evaluate atomoxetine treatment effects in attention-deficit/hyperactivity disorder
(ADHD-only), attention-deficit/hyperactivity disorder with comorbid dyslexia (ADHD +D), or dyslexia only onADHD core
symptoms and on sluggish cognitive tempo (SCT), working memory, life performance, and self-concept.
Methods: Children and adolescents (10–16 years of age) with ADHD +D (n = 124), dyslexia-only (n = 58), or ADHD-
only (n = 27) received atomoxetine (1.0–1.4 mg/kg/day) or placebo (ADHD-only subjects received atomoxetine) in a 16
week, acute, randomized, double-blind trial with a 16 week, open-label extension phase (atomoxetine treatment only).
Changes from baseline were assessed to weeks 16 and 32 in ADHD Rating Scale-IV-Parent-Version:Investigator-
Administered and Scored (ADHDRS-IV-Parent:Inv); ADHD Rating Scale-IV-Teacher-Version (ADHDRS-
IV-Teacher-Version); Life Participation Scale—Child- or Parent-Rated Version (LPS); Kiddie-Sluggish Cognitive
Tempo (K-SCT) Interview; Multidimensional Self Concept Scale (MSCS); and Working Memory Test Battery for
Children (WMTB-C).
Results:Atweek 16, atomoxetine treatment resulted in significant ( p < 0.05) improvement from baseline in subjects with
ADHD +D versus placebo on ADHDRS-IV-Parent:Inv Total (primary outcome) and subscales, ADHDRS-IV-Teacher-
Version Inattentive subscale, K-SCT Interview Parent and Teacher subscales, and WMTB-C Central Executive
component scores; in subjects with Dyslexia-only, atomoxetine versus placebo significantly improved K-SCT Youth
subscale scores from baseline. At Week 32, atomoxetine-treated ADHD +D subjects significantly improved from
baseline on all measures except MSCS Family subscale and WMTB-C Central Executive and Visuo-spatial Sketchpad
component scores. The atomoxetine-treated dyslexia-only subjects significantly improved from baseline to week 32 on
ADHDRS-IV-Parent:Inv Inattentive subscale, K-SCT Parent and Teacher subscales, and WMTB-C Phonological Loop
and Central Executive component scores. The atomoxetine-treated ADHD-only subjects significantly improved from
baseline to Week 32 on ADHDRS-Parent:Inv Total and subscales, ADHDRS-IV-Teacher-Version Hyperactive/Im-
pulsive subscale, LPS Self-Control and Total, all K-SCT subscales, and MSCS Academic and Competence subscale
scores.
Conclusions: Atomoxetine treatment improved ADHD symptoms in subjects with ADHD +D and ADHD-only, but not in
subjects with dyslexia-only without ADHD. This is the first study to report significant effects of any medication on SCT.
Clinical Trials Registration: This study was registered at: http://clinicaltrials.gov/ct2/home, NCT00607919.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) anddyslexia frequently co-occur (ADHD with comorbid dyslexia
[ADHD +D]) (Germano et al. 2010). It has been hypothesized that
common genetic influences and neuropsychological deficits are
associated with an increased susceptibility for both disorders
(Willcutt et al. 2007, 2010). Those shared genetic variables seem to
mainly connect reading difficulties and ADHD inattention symp-
toms, while being largely independent of genes that contribute to
general cognitive ability (Paloyelis et al. 2010). Shared cognitive
deficits for both ADHD and dyslexia include weaknesses on mea-
sures of phoneme awareness, verbal reasoning, and working
memory (Willcutt et al. 2010). Patients with ADHD and those with
dyslexia report lower life performance and an impaired self-
concept (Smith-Spark et al. 2004; Houck et al. 2011; Ridley 2011;
Brod et al. 2012). It has been suggested that attention difficulties
associated with ADHDmay be a causal factor for reading difficulties
in some patients with dyslexia (Shaywitz and Shaywitz 2008).
The inattention dimension of ADHD symptoms is associated
with an experimental construct termed Sluggish Cognitive Tempo
(SCT), which emerges as a dimension separate from inattention and
hyperactivity/impulsivity in exploratory (McBurnett et al. 2001;
Hartman et al. 2004; Penny et al. 2009) and confirmatory (Hartman
et al. 2004; Garner et al. 2010) factor analyses. The core features of
SCT are excessive daydreaming, hypoactivity or slowness, and
drowsiness. External correlates have included internalizing co-
morbidities (Carlson and Mann 2002; Hartman et al. 2004; Penny
et al. 2009; Garner et al. 2010; Skirbekk et al. 2011) and some
neuropsychological abnormalities (Hinshaw et al. 2002; Huang-
Pollock et al. 2005; Yee Mikami et al. 2007; Wahlstedt and Bohlin
2010; Skirbekk et al. 2011). Neuropsychological performance in
ADHD appears more affected by inattention than by other di-
mensions of the disease. Although SCT has often been studied as a
dimensional aspect of ADHD, it has also been observed to occur in
other pathologies in children. Reeves and coinvestigators observed
SCT as a sequela of acute lymphoblastic leukemia in children
(Reeves et al. 2007). Additionally, SCT has been described as an
independent condition of ADHD, and is associated with serious
impairment in adults (Barkley 2012).
To date, only a limited number of trials have evaluated possible
interventions for patients withADHD+D (Sexton et al. 2012) and no
trials, to our knowledge, have evaluated the effects of medication on
SCT. Recently, two small clinical trials suggested that atomoxetine
is effective in the treatment of ADHD symptoms in children and
adolescents with ADHD+D (de Jong et al. 2009; Sumner et al.
2009). The first study examined the effect, on reading performance
and on neurocognitive function, of open-label treatment with
atomoxetine in subjects with ADHD+D (n= 36) or ADHD-only
(n= 20), 10–16 years of age (Sumner et al. 2009). Treatment with
atomoxetine resulted in reduced ADHD symptoms and improved
reading scores in both groups; however, the authors observed dif-
ferent patterns and magnitudes of improvement in the working
memory component scores in the different subject groups (Sumner
et al. 2009). The second study was a randomized, placebo-controlled
crossover study (de Jong et al. 2009). Enrolled were subjects with
ADHD+D (n= 20), dyslexia-only (n= 21), and ADHD-only
(n= 16), and healthy controls (n= 26), 9–10 years of age. In this
study, treatment with atomoxetine, compared with placebo, im-
proved visuospatial working memory performance and inhibition in
subjects with ADHD+D, whereas no effects were seen in the dys-
lexia-only and ADHD-only groups (de Jong et al. 2009).
Here, we evaluated the efficacy and safety of atomoxetine in
children and adolescents with ADHD +D, dyslexia-only, and
ADHD-only in a larger, randomized, placebo-controlled trial. We
tested the a priori hypothesis that atomoxetine given orally once
daily (QD) for *16 weeks would provide superior efficacy com-
pared with placebo for the treatment of ADHD in children and
adolescents with ADHD +D. Secondary objectives sought to
evaluate the effects of atomoxetine in children and adolescents with
dyslexia-only, and atomoxetine’s effects on SCT, working mem-
ory, life performance, and self-concept in children and adolescents
with ADHD +D, dyslexia-only, or ADHD-only.
Methods
Subjects
Subjects with ADHD +D and ADHD-only met Diagnostic and
Statistical Manual of Mental Disorders, 4th ed., Text Revision
(American Psychiatric Association 2000) diagnostic criteria for
ADHD; this was confirmed during visit 1 by the Kiddie Schedule
for Affective Disorders and Schizophrenia for School-Aged
Children-Present and Lifetime Version—Behavioral Component
(Kaufman et al. 1997). At visits 2 and 3, subjects with ADHD +D
and ADHD-only also had an ADHD Rating Scale-IV-Parent-
Version:Investigator-Administered and Scored (ADHDRS-IV-
Parent:Inv) Total score ‡ 1.5 standard deviations above age and
gender norms. Subjects with ADHD +D and dyslexia-only met
criteria for dyslexia at Visit 2: ‡ 22-point discrepancy between the
Wechsler Abbreviated Scale of Intelligence Verbal Intelligence
Quotient or Performance Intelligence Quotient (whichever was
higher) and the Woodcock Johnson III Basic Reading Skills score,
Letter Word Identification score, or Word Attack score; or a score
£ 89 on any of the aforementioned Woodcock Johnson III sub-
scales. Excluded were subjects with a documented history of bi-
polar I or bipolar II disorder, psychosis, autism, Asperger’s
syndrome, or pervasive developmental disorder, and subjects who
were currently taking anticonvulsants for seizure control.
Sample size calculations were based on the primary analysis of
the difference in the ADHDRS-IV-Parent:Inv Total score between
subjects with ADHD +D taking atomoxetine and those taking
placebo. A last observation carried forward approach with 65
subjects per arm would allow for a two sided test at the 5% sig-
nificance level, with an assumed effect size of 0.60, 90% power,
and a missing data rate of 5%. At an effect size of 0.65, the power
would increase to 94%; at an effect size of 0.70, the power would be
96%; and at an effect size of 0.55, the study would have 85% power.
Previous studies comparing atomoxetine and placebo had effect
sizes ranging from 0.63 to 0.80.
Study design
The design was a multicenter, randomized, placebo-controlled,
double-blind phase 4 study of atomoxetine (0.5mg/kg/day for 3
days, then 1.0–1.4mg/kg/day) administered QDwith food followed
by a 16 week, open-label, extension phase. After nearly 2 weeks of
screening, subjects with ADHD +D and dyslexia-only were ran-
domized to atomoxetine or placebo treatment in a 1:1 ratio by a
computer-generated, random sequence using an interactive voice
response system. Subjects with ADHD-only received atomoxetine
for 16 weeks, but they were told that at some point during the acute
phase they might be placed on placebo to help mitigate the potential
for an open-label bias. After finishing the acute phase, subjects
could enter the extension phase and receive atomoxetine QD
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(0.5mg/kg/day for a minimum of 3 days, then 1.0–1.4mg/kg/day)
with food. Before study initiation, the protocol was reviewed and
approved by the appropriate institutional review boards. Parents or
guardians of all patients provided written informed consent before the
subjects received study medication or underwent study procedures.
Efficacy measures
Assessed were changes from baseline to weeks 16 and 32 in
ADHDRS-IV-Parent:Inv (DuPaul et al. 1998) (raw scores; inves-
tigators administered the scale to parents; 18 item scale, total score
ranges from 0 to 54 with each item scored on a 0–3 scale: 0 = never
or rarely [none]; 1 = sometimes [mild]; 2 = often [moderate];
3 = very often [severe]); ADHDRS-IV-Teacher-Version (raw
scores; teacher completed 18 item scale, total score ranges from 0 to
54 with each item scored on a 0–3 scale:0= never or rarely [none];
1 = sometimes [mild]; 2 = often [moderate]; 3= very often [se-
vere]); Life Participation Scale—Child-, Parent-Rated Version
(LPS; raw scores; 24 item scale; total score ranges from 0 to 72
with each item scored on a 0–3 scale: 0 = never or seldom;
1 = sometimes; 2 = often; 3= very often); Kiddie-Sluggish Cogni-
tive Tempo (K-SCT; raw scores; 17 item scale; total score ranges
from 0 to 51 with each item scored on a 0–3 scale: 0= never or
rarely; 1 = sometimes; 2= often; 3 = very often) (Lee et al. 2013);
Multidimensional Self Concept Scale (MSCS; age-based standard
scores; 150 item scale composed of six scales and a total score
that ranges from 45 to 145; items are differentially scored based
on positively worded items: 1= strongly disagree; 2= disagree;
3 = agree; 4= strongly agree; or negatively worded items:
4 = strongly disagree; 3 = disagree; 2= agree; 1 = strongly agree);
and Working Memory Test Battery for Children (WMTB-C; age-
based standard scores; scale consists of nine subtests that measure
three components; scores for these three components range from
55 to 145).
Statistical analyses
We tested the a priori hypothesis that atomoxetine QD for*16
weeks would provide superior efficacy compared with placebo for
the treatment of ADHD in children with ADHD +D. The pre-
specified primary analysis for the trial was a mixed-effects repeated
measures model (MMRM) with terms for treatment, investigator,
baseline score, visit, treatment by visit, and baseline score by visit,
on the ADHDRS-IV-Parent:Inv Total score comparing atomox-
etine and placebo in subjects with ADHD +D after 16 weeks. Only
the primary analysis was conducted with MMRM.
Secondary objectives sought to evaluate the effects of atomox-
etine in children and adolescents with dyslexia-only, and atomox-
etine’s effects on SCT, working memory, life performance, and
self-concept in children and adolescents with ADHD-only, dys-
lexia-only, or ADHD-only. These efficacy data were analyzed with
last observation carried forward analyses that used fixed-effects
analysis of covariance (ANCOVA)models with terms for treatment
group, investigator, sex, baseline score, age, and baseline score-by-
treatment interaction. Similar ANCOVA models were used to
assess diagnostic group differences with terms for diagnosis, in-
vestigator, sex, baseline score, age, and baseline score-by-diagnosis
interaction in both acute and open-label phases. Type III sums of
squares were used for between-treatment tests. Changes within
treatment were assessed using Student’s t test applied to the least-
squares mean for the group from the ANCOVA model. In retro-
spect, the adjustment for baseline scores may not have been an
appropriate analysis for scales that specifically measure ADHD
symptoms, as all patients did not have ADHD; therefore, this ad-
justment could have obscured a difference when an overall mean
was used across diagnoses in calculation of least-squares mean,
thereby inflating the scores in the dyslexia-only group, up to levels
consistent with ADHD +D. Also, effects of baseline and baseline
score-by-treatment interaction could have been overinfluenced by
ADHD +D patients, given the larger variability of baseline values
for this group of patients. To evaluate this possibility, means and p
values that ignore baseline were also examined for ADHDRS-IV-
Parent:Inv, ADHDRS-IV-Teacher-Version, and LPS with the
ANCOVA approach described, excluding the terms for baseline
score and baseline score-by-treatment interaction. Secondary end-
points were not adjusted for testing of multiple hypotheses, as we
wanted to show the actual results that could identify areas in which
more research could be warranted.
To determine whether improvements in ancillary measures were
a byproduct of the ADHD improvement, Pearson’s correlation
coefficients were determined between changes in K-SCT scores
(Parent, Teacher, and Youth subscales) and ADHDRS-IV-
Parent:Inv/ADHDRS-IV-Teacher-Version (Total and Inattentive
and Hyperactive/Impulsive subscales), as well as among demo-
graphic baseline parameters (age, gender, income status, education,
and ADHD subtype) and all outcome measures at 16 and 32 weeks.
Results
Subjects’ disposition and baseline demographics
A total of 333 subjects were screened for study eligibility, of
which 209 subjects were randomized for the acute treatment phase
(Fig. 1). The acute treatment phase was completed by 86 subjects in
the atomoxetine group and 73 subjects in the placebo group. Of these
subjects, 84 subjects who had received atomoxetine and 71 subjects
who had received placebo entered the extension phase. The exten-
sion phase was completed by a total of 133 subjects (Fig. 1).
During the acute treatment phase,*62% of subjects in both the
atomoxetine and placebo groups were male, with a mean age of 12
years. Most subjects were diagnosed with inattentive ADHD (ato-
moxetine: 50%; placebo: 54%), followed by combined ADHD
(atomoxetine: 49%; placebo: 43%). These demographic parameters
were similar during the extension phase (Supplementary Table 1)
(see online Supplementary Material at http://www.liebertonline.com).
Efficacy results – acute phase
The result of the primary MMRM analysis was significant
( p< 0.001) and showed greater improvement on the ADHDRS-IV-
Parent:Inv Total score for atomoxetine-treated subjects with
ADHD +D than for placebo-treated subjects with ADHD +D
( - 20.0 vs. - 12.3, respectively). When data were analyzed using
ANCOVA with an adjustment for baseline scores, significant
( p< 0.05) improvements on the ADHDRS-IV-Parent:Inv Total
score, and Inattentive and Hyperactive/Impulsive subscale scores,
were seen in response to treatment with atomoxetine in subjects
with ADHD +D, dyslexia-only, and ADHD-only. When compared
with subjects on placebo, however, improvements after treatment
with atomoxetine were significantly different for subjects with
ADHD +D, but not for subjects with dyslexia-only (Supplementary
Table 2) (see online Supplementary Material at http://www
.liebertonline.com).
When data were analyzed without an adjustment for baseline
scores, no significant improvements during treatment with ato-
moxetine on the ADHDRS-Parent:Inv Total and subscale scores
ATOMOXETINE IN ADHD WITH DYSLEXIA 607
were observed for subjects with dyslexia-only, wheras improve-
ments from baseline were significant for subjects with ADHD +D
and ADHD-only (Table 1).
Improvements on the ADHDRS-IV-Teacher-Version Total score,
and Inattentive and Hyperactive/Impulsive subscales, after acute
treatment with atomoxetine, were significant for subjects with
ADHD+D, but not for subjects with ADHD-only when analyzed
with an adjustment for baseline scores; subjects with dyslexia-only
showed significant improvements only on the Inattentive subscale
(Supplementary Table 2). When data were not adjusted for baseline
scores, only subjects with ADHD+D showed significant improve-
ments during treatment with atomoxetine on ADHDRS-IV-Teacher-
Version Total scores and Inattentive subscale scores (Table 1).
On the LPS, changes from baseline, during treatment with ato-
moxetine, were significant for subjects with ADHD +D for the
Self-Control subscale and the Total score, when data were analyzed
either adjusted or unadjusted for baseline scores (Supplementary
Tables 2 and 3) (see online Supplementary Material at http://
www.liebertonline.com). For subjects with ADHD-only, changes
from baseline were significant during treatment with atomoxetine
on the Self-Control subscale and the LPS Total score, when data
were analyzed adjusted for baseline scores (Supplementary Table
2). Analysis of data unadjusted for baseline scores also showed
significant changes on the Happy/Social subscale (Supplementary
Table 3). It was assumed that analyses of score changes on the K-
SCT, MSCS and WMTB-C were not biased as these scales did not
specifically measure ADHD symptoms. The MSCS and WMTB-C
have been used in assessments of patients with multiple disease
states (Bracken 1992; Pickering and Gathercole 2001). The K-SCT
is a construct that is currently being researched, and there are some
data to support SCT as a separate disorder fromADHD (Penny et al.
2009; Garner et al. 2010; Barkley and Fischer 2011). Therefore,
analyses of changes on K-SCT, MSCS, and WMTB-C were only
performed with the a priori defined model, including an adjustment
for baseline scores. Subjects with ADHD +D experienced signifi-
cantly greater improvements during treatment with atomoxetine
compared with placebo on K-SCT Parent and Teacher subscales
(Table 1). On MSCS subscales, no significant treatment group
differences were observed for subjects with ADHD +D, and on
WMTB-C, only the Central Executive component score was sig-
nificantly more improved during treatment with atomoxetine than
with placebo in subjects with ADHD +D (Supplementary Table 3).
Most effect sizes ranked from moderate to large for statistically
significant differences between atomoxetine and placebo treatment
(Table 1 and Supplementary Table 3). Comparison of score chan-
ges during atomoxetine treatment among subjects with ADHD +D,
dyslexia-only, and ADHD-only yielded no significant differences
in either the baseline score-adjusted or -unadjusted analyses (Table
1 and Supplementary Table 3).
After 16 weeks, change in the K-SCT Parent subscale score was
significantly correlated with changes in ADHDRS-IV-Parent:Inv
scores (correlation coefficient of 0.40–0.54, p< 0.001); and change in
the K-SCT Teacher subscale score was significantly correlated with
changes in ADHDRS-IV-Teacher-Version scores (correlation coef-
ficient of 0.33–0.61, p£ 0.004) (Supplementary Table 4) (see online
supplementary material at http://www.liebertonline.com). All corre-
lations were positive, showing that as ADHDRS scores improved so
did K-SCT scores. The change in the K-SCT Youth subscale score
showed a significant, but weak, correlation with changes in
ADHDRS-Parent:Inv scores (correlation coefficient of 0.16–0.19,
p£0.032), but not in ADHDRS-IV-Teacher-Version scores. None of
the examined baseline demographic parameters showed significant
correlations with any of the presented outcome measures.
Efficacy results—extension phase
When analyzed with an adjustment for baseline scores, signifi-
cant ( p < 0.05) improvements on the ADHDRS-Parent:Inv Total
score, and Inattentive and Hyperactive/Impulsive subscale scores,
were seen in response to treatment with atomoxetine in subjects
with ADHD +D, Dyslexia-only, and ADHD-only, after 32 weeks
(Supplementary Table 2). When data were analyzed unadjusted for
baseline scores, improvements remained significant for subjects
with ADHD +D and ADHD-only for ADHDRS-Parent:Inv Total
and subscale scores; in subjects with dyslexia-only, only changes
from baseline on the Inattentive subscale remained significant
(Table 2). Total score changes and changes on both subscales of the
ADHDRS-Parent:Inv were significantly different between subjects
with ADHD +D and those with dyslexia-only, when data were not
adjusted for baseline scores.
FIG. 1. Flow diagram of subject disposition during the acute and extension phases.
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Improvements on the ADHDRS-IV-Teacher-Version Total score,
and Inattentive and Hyperactive/Impulsive subscales, during exten-
sion phase treatment with atomoxetine, were significant for subjects
with ADHD+D, when analyzed with an adjustment for baseline
scores; subjects with dyslexia-only showed significant improve-
ments on the Total score and Inattentive subscale score, while sub-
jects with ADHD-only showed significant improvements on the
Hyperactive/Impulsive subscale score (Supplementary Table 2).
When data were not adjusted for baseline scores, only subjects with
ADHD+D showed significant improvements during treatment with
atomoxetine on the ADHDRS-IV-Teacher-Version Total score and
Inattentive subscale score, and subjects with ADHD-only showed
significant improvements during treatment with atomoxetine on the
Hyperactive/Impulsive subscale score (Table 2).
Changes from baseline on LPS during extension phase treatment
with atomoxetine were significant for subjects with ADHD +D for
the Happy/Social subscale, the Self-Control subscale, and the Total
scores, when data were analyzed adjusted for baseline scores
(Supplementary Table 5) (see online Supplementary Material at
http://www.liebertonline.com); without adjustment for baseline
scores, changes on LPS Total and both subscales were significant
(Supplementary Table 6) (see online Supplementary Material at
http://www.liebertonline.com). For subjects with ADHD-only,
changes were significant on the Self-Control subscale and the LPS
Total score when data were analyzed adjusted or unadjusted for
baseline scores (Supplementary Tables 2 and 5). In subjects with
dyslexia-only, changes were significant on the Self-Control sub-
scale score and the LPS Total score when data were analyzed ad-
justed for baseline scores (Supplementary Table 6); no significant
changes on the LPS Total score or either of the subscale scores were
observed in subjects with dyslexia-only when data were not ad-
justed for baseline scores (Supplementary Table 5).
Similar to the acute treatment phase, in the extension phase it
was assumed that analyses of score changes on the K-SCT Inter-
view, MSCS, and WMTB-C were not biased, as these tests do not
specifically measure ADHD symptoms; therefore, analyses were
performed only with the a priori defined model that included an
adjustment for baseline scores. Subjects with ADHD +D and
ADHD-only experienced significant improvements on all K-SCT
Interview subscales, whereas changes reached significance only for
the Parent and Teacher subscales for subjects with dyslexia-only;
changes were significantly different between subjects with
ADHD +D and subjects with dyslexia-only for the K-SCT Parent
subscale (Table 2). On theMSCS, changes in the Total score and all
subscales, except the Family subscale, reached significance for
subjects with ADHD +D; for subjects with dyslexia-only, no sig-
nificant changes were observed; for subjects with ADHD-only, the
Academic and the Competence subscales showed significant
changes. On theWMTB-C, only the Phonological Loop component
score was significantly improved in subjects with ADHD +D; in
subjects with dyslexia-only, changes on the Phonological Loop
component and on the Central Executive component reached sig-
nificance; in subjects with ADHD-only, no significant changes
were observed (Supplementary Table 5).
After 32 weeks, change in the K-SCT Interview Parent subscale
score was significantly correlated with changes in ADHDRS-
Parent:Inv scores (correlation coefficient of 0.48–0.63, p< 0.001),
and change in the K-SCT Interview Teacher subscale score was
significantly correlated with changes in ADHDRS-IV-Teacher-
Version scores (correlation coefficient of 0.46–0.71, p £ 0.003)
(Supplementary Table 7) (see online Supplementary Material at
http://www.liebertonline.com). All correlations were positive, and
showed that as K-SCT scores improved so did ADHDRS scores.
The change in the K-SCT Youth subscale score showed a signifi-
cant, but weak, correlation with changes in ADHDRS-Parent:Inv
Inattentive and Total scores (correlation coefficient of 0.20–0.24,
p £ 0.016), but not the ADHDRS-IV-Teacher-Version scores. The
baseline demographic parameter ‘‘ADHD subtype’’ was negatively
correlated with ADHDRS-Parent:Inv scores (correlation coeffi-
cient of - 0.70 to - 0.48, p£ 0.031) in ADHD-only patients, as well
as with the MSCS Academic subscale score in dyslexia-only pa-
tients (correlation coefficient of - 0.62, p= 0.041). No other
baseline demographic parameters showed strong and significant
correlations to any of the presented outcome measures.
Table 2. Efficacy Results—Week 32
ADHD +D Dyslexia-only ADHD-only
Measure n Baseline
LSMean (mean)
change n Baseline
LSMean (mean)
change n Baseline
LSMean (mean)
change pa pb
ADHDRS-IV-Parent Version: Inv (no adjustment for baseline score)
Total 45 37.18 - 21.59*** ( - 23.64) 18 15.00 - 5.68 ( - 8.61) 21 34.95 - 19.57*** ( - 22.62) < 0.001 0.453
Inattentive 45 22.42 - 13.84*** ( - 12.92) 18 10.28 - 4.14* ( - 5.67) 21 22.38 - 12.12*** ( - 14.33) < 0.001 0.659
Hyp/Imp 45 14.76 - 8.67*** ( - 9.80) 18 4.72 - 1.54 ( - 2.94) 21 12.57 - 7.45*** ( - 8.29) < 0.001 0.443
ADHDRS-IV-Teacher Version (no adjustment for baseline score)
Total 23 23.97 - 9.05** ( - 6.15) 11 15.55 - 6.88 ( - 6.76) 9 21.00 - 8.39 ( - 7.08) 0.903 0.875
Inattentive 23 16.02 - 5.19* ( - 4.28) 11 10.27 - 3.65 ( - 4.03) 9 13.00 - 3.96 ( - 4.19) 0.713 0.707
Hyp/Imp 23 7.96 - 3.86** ( - 1.87) 11 5.27 - 3.23 ( - 2.73) 9 8.00 - 4.43* ( - 2.89) 0.695 0.752
K-SCT Interview (adjusted for baseline score)
Parent 45 22.09 - 9.97*** ( - 10.40) 18 8.12 - 14.67***( - 3.68) 21 21.03 - 10.50*** ( - 10.83) 0.038 0.812
Teacher 23 22.87 - 7.56** ( - 7.00) 11 14.49 - 11.53* ( - 5.40) 9 17.00 - 10.62* ( - 7.89) 0.455 0.547
Youth 45 18.71 - 4.96** ( - 4.36) 18 14.61 - 4.17 ( - 2.00) 21 19.29 - 4.78** ( - 5.43) 0.921 0.929
aADHD+D (atomoxetine) versus Dyslexia-only (atomoxetine) p value.
bADHD+D (atomoxetine) versus ADHD-only (atomoxetine) p value.
Intra-group p values: *p< 0.05; **p< 0.01; ***p< 0.001; p values from t tests on LSMean change.
ADHD, attention deficit/hyperactivity disorder; ADHDRS-IV-Parent:Inv, ADHD Rating Scale-IV-Parent-Version:Investigator-Administered and
Scored; ADHDRS-IV-Teacher Version, ADHD Rating Scale-IV-Teacher-Version; K-SCT, Kiddie-Sluggish Cognitive Tempo; Hyp/Imp, Hyperactive/
Impulsive; LSMean, least squares mean.
610 WIETECHA ET AL.
Safety
Overall, atomoxetine was well tolerated and the treatment-
emergent adverse event (TEAE) profiles in both acute and ex-
tension phases were consistent with previous reports (Sumner
et al. 2009). The most frequently observed TEAEs with atomox-
etine treatment were nausea, fatigue, and upper abdominal pain
(Table 3).
Discussion
In this randomized, placebo-controlled trial, we tested the a
priori hypothesis that atomoxetine QD for *16 weeks would
provide superior efficacy compared with placebo for the treatment
of ADHD in children and adolescents with ADHD +D. Atomox-
etine treatment resulted in significant improvements of several
well-established measures of ADHD symptoms in children and
adolescents with ADHD +D or ADHD-only, but, as expected, not
in subjects with dyslexia-only. These ADHD symptom improve-
ments were maintained during an open-label extension phase.
Neither during the acute nor during the open-label treatment phases
were significant differences in ADHD symptom improvements
noted between atomoxetine-treated subjects with ADHD +D and
those with ADHD-only. Our results support the findings of previ-
ous, smaller studies that show efficacy of atomoxetine treatment in
children with ADHD +D (de Jong et al. 2009; Sumner et al. 2009).
Demonstrating efficacy of atomoxetine in children with a co-
morbidity of ADHD +D comparable to its efficacy in children with
ADHD-only is an important finding for clinicians faced with
treatment decisions.
Adjustment for baseline disease characteristics
In the a priori analysis plan of this study, an adjustment for
baseline disease characteristics was included to control for po-
tential baseline differences between treatment groups; however,
the authors realized, retrospectively, that this adjustment might
have overcorrected these between-treatment-group differences,
especially for the subjects with dyslexia-only. This subject
group was not symptomatic for ADHD, and all ADHD-specific
measures produced signals within the background noise level.
Although this result was expected, the adjustment for baseline
disease characteristic resulted in an unexpected effect—it am-
plified ADHD symptom signals within this group of subjects,
and it artificially created significant changes. Therefore, the
authors decided to repeat the analyses without an adjustment for
baseline disease characteristics, which eliminated this artificial
signal.
SCT
SCT has been shown to be responsive to psychosocial treatment
(Pfiffner et al. 2007); however, to our knowledge, this is the first
study to report a significant effect of any medication on SCT. Al-
though this finding might be the result of chance because of the high
number of comparisons that were performed in the current analyses,
our results are interesting, in light of recent studies that identified a
subset of patients with ADHD who have SCT, marked by sluggish-
lethargic behavior, hypoactivity, and mental confusion (Barkley
2012). Currently, no information is available to indicate which
percentage of patients with ADHD+D and ADHD-only could be
classified as SCT. It is not yet clear whether SCT is a subtype or a
completely different entity of ADHD (Penny et al. 2009). Some
research supports the hypothesis that SCT and ADHD are distinct
disorders with a high rate of comorbidity in affected individuals
(Barkley 2012; Lee et al. 2013). Based on this research, we decided
not to adjust SCT scores for baseline levels within our analyses. In
consideration of shared genetic variables between ADHD and dys-
lexia, which seem to mainly connect reading difficulties and ADHD
inattention symptoms (Paloyelis et al. 2010), one might expect a
significant percentage of patients with ADHD+D to be affected by
SCT. Future studies that examine those disease characteristics, and
the potential differences in treatment response that might be asso-
ciated with these classifications, are warranted.
Study limitations
Several factors limit the interpretation of our results. Overall, a
higher percentage of subjects with Inattentive ADHD subtype
participated in this study compared with previous studies, which,
therefore, limits its comparisons with previous results. Excluding
6–10-year-old subjects contributes to a higher percentage of sub-
jects with Inattentive ADHD; however, this observation might also
reflect a higher likelihood of comorbidity with dyslexia in subjects
with inattentive ADHD, and this likelihood would be supported by
the connection of reading difficulties and ADHD inattention
symptoms and by shared genetic variables between ADHD and
dyslexia (Paloyelis et al. 2010). The results of our study also
heavily relied on parent ratings, with very few measures in aca-
demic settings and low teacher participation, which could account
for teacher ratings not reaching significance, whereas parent ratings
reached significance on a number of measures. During individual
clinic visits, a relatively large number of measures were adminis-
tered to the subjects typically late in the afternoon after school, and
this might have promoted exhaustion and biased the data. Finally,
the validity of our results is limited to subjects 10–16 years of age.
Table 3. Treatment-Emergent Adverse Events in ‡ 5% of Subjects in Either Treatment Group
and Statistically Significantly Differences Between Treatment Groups
Acute phase Extension phase
ATX (n= 120) PLB (n= 89) p value ATX/ATX (n = 84) PLB/ATX (n = 71)
Subjects with ‡ 1 event 108 (90.0) 71 (79.8) 0.046 40 (47.6) 46 (64.8)
Nausea 34 (28.3) 5 (5.6) < 0.001 2 (2.4) 8 (11.3)
Fatigue 31 (25.8) 9 (10.1) 0.004 3 (3.6) 9 (12.7)
Upper abdominal pain 23 (19.2) 6 (6.7) 0.014 1 (1.2) 6 (8.5)
Decreased appetite 22 (18.3) 4 (4.5) 0.003 2 (2.4) 9 (12.7)
Somnolence 10 (8.3) 0 0.006 NA NA
Aggression 6 (5.0) 1 (1.1) 0.039 NA NA
ATX, atomoxetine; NA, not available; PLB, placebo.
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Conclusions
This study demonstrates the efficacy of atomoxetine in the
treatment of ADHD core symptoms as observed by parents, in
children and adolescents with ADHD +D and ADHD-only.
Clinical Significance
The inattention dimension of ADHD symptoms has been asso-
ciated with the experimental construct of SCT. This is the first study
to report a significant effect of any medication on SCT.
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